Contrasting Autonomix Medical (NASDAQ:AMIX) & NeuroPace (NASDAQ:NPCE)

Autonomix Medical (NASDAQ:AMIX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Autonomix Medical and NeuroPace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1	1	1	0	2.00
NeuroPace	1	1	4	2	2.88

Autonomix Medical currently has a consensus target price of $2.00, indicating a potential upside of 400.00%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 13.87%. Given Autonomix Medical’s higher probable upside, research analysts plainly believe Autonomix Medical is more favorable than NeuroPace.

Institutional & Insider Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Autonomix Medical and NeuroPace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-239.36%	-192.46%
NeuroPace	-21.67%	-108.20%	-18.50%

Risk & Volatility

Autonomix Medical has a beta of -1.44, indicating that its stock price is 244% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares Autonomix Medical and NeuroPace”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$16.72 million	($3.55)	-0.11
NeuroPace	$99.99 million	5.64	-$21.47 million	($0.65)	-25.45

Autonomix Medical has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Summary

NeuroPace beats Autonomix Medical on 10 of the 14 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.